Most weeks in theranostics news are incremental: a trial readout here, a label tweak there. This week was different. On a single Monday the FDA approved the first amino acid PET agent for brain tumors in the United States and the first alternative to Lutathera.

Pixclara: FET PET is finally here

Telix announced FDA approval of Pixclara (floretyrosine F 18, or ¹⁸ F-FET), an amino acid PET drug for imaging gliomas. The indication is specific. It is used to differentiate recurrent or progressive glioma from treatment-related change, in conjunction with other diagnostic evaluations, in adults and pediatric patients 1 month of age and older.

This is the kind of question that keeps neuro-oncology tumor boards up at night. A patient finishes chemoradiation, the follow-up MRI shows new enhancement, and nobody can say with confidence whether it is tumor or treatment effect. FET gives a biological answer. It targets the L-type amino acid transporters LAT1 and LAT2, which are upregulated in glioma.

The approval took a while. The FDA issued a complete response letter for the original application in April 2025, and Telix resubmitted with additional data and statistical analyses in March 2026. FET PET has been standard in Europe for years and appears in the NCCN Guidelines for Central Nervous System Cancers and in joint EANM/EANO/SNMMI/RANO guidance. Outside of research protocols, American patients had no approved option until now.

What FET PET means for Appalachia

From an ARC perspective, this approval matters because it is a diagnostic that runs on equipment our region already has. You just need a PET/CT scanner, a supply of an F-18 product, and a reader who knows what they are looking at. This provides advanced disease assessment close to home so folks in our region can potentially access higher quality care.

That last requirement is the hard one. FET interpretation is not FDG interpretation. Tumor-to-background ratios, time-activity curve patterns, and the pitfalls around inflammation and recent surgery all take training. The label carries a warning about image misinterpretation risk, which is the FDA's polite way of saying the scan is only as good as the person reading it. For community sites that want to offer FET locally rather than sending glioma patients three hours each way to an academic center, reader education is the gating step. That is squarely in ARC's lane, and we will build it into our training materials.

Bexlutry: a second source of lutetium dotatate

The same day, Curium announced FDA approval of Bexlutry (lutetium Lu 177 dotatate injection) for adults with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors, including foregut, midgut, and hindgut disease. Curium states the product is already available for prescribing.

Since 2018, if your patient needed PRRT for a GEP-NET in this country, there was exactly one product and one supply chain. That is no longer true.

A note on the word "generic"

You will see Bexlutry called a generic Lutathera in the trade press. Strictly speaking, it isn't. Curium describes it as a radioligand equivalent approved through the 505(b)(2) pathway, supported by published evidence and targeted bridging data. A 505(b)(2) is a full NDA that is allowed to lean on someone else's clinical data. The true generic route is the ANDA, and Lantheus received tentative approval in March for its ANDA for PNT2003, with final approval tied to a Hatch-Waxman 30-month stay that was set to expire in June 2026.

Two pathways were aimed at the same molecule, and the 505(b)(2) reached the clinic first. That is a useful lesson for anyone predicting how the next wave of radiopharmaceutical copies will arrive.

Why a second source matters more here than it does for pills

For a conventional drug, generics mostly mean lower prices. For a radiopharmaceutical, an additional important benefit is redundancy. Lutetium-177 has a 6.6-day half-life. You cannot stockpile it. When a reactor goes down or a production run fails, the patient's treatment date slips. Anyone who has rescheduled a PRRT cycle because the dose didn't ship knows that the single-source era had a real cost, and it was paid disproportionately by sites far from a distribution hub. A second manufacturer with its own supply chain is a resilience improvement for every community program in our corridor.

The bigger picture

We are entering the era of radiopharmaceutical copies, and I suspect it will not look like the small-molecule generic market. Manufacturing capacity, isotope supply, and regulatory pathway choice will determine who gets to market, more than chemistry will. It is also worth noting that Curium announced a definitive agreement to merge with Lantheus in August, so both Lutathera alternatives may eventually sit under one corporate roof. How much that tempers the competition story remains to be seen.

For patients in Appalachia, the net result of this week is simple. There is one more reason for glioma patients to get their answer closer to home, and one fewer single point of failure standing between NET patients and their scheduled treatment. And I hold out hope that new competition will also spur pricing movements that help bring radiopharmaceutical therapies into broader reach.

Is your site planning to evaluate either product? What questions would you want answered before bringing FET PET or a second lutetium source into your workflow?